Pengaruh Pentoxifylline terhadap Kadar Asam Hialuronat Serum pada Penderita Hepatitis Kronis B

Abstract

Background Almost 400 million people in the world had suffered from chronic hepatitis B and 15 - 40% of them will be going to be cirrhotic and end stage liver disease.· Cirrhotic and end stage liver disease were due to fibrotic process in chronic damage of the liver. Nowadays study has showed that liver fibrosis is a reversible process. Neutralisation of respond of Hepatic stellate cell (HSC) by inhibition fibrogenic signaling transduction is one of the method to treat liver fibrosis. Pentoxifylline is a drug that act by modulating fibrogenic signaling transduction and would give an antifibrotic effect to liver fibrosis. Objective To assess the decreased of hyaluronic acid (HA) serum level on chronic hepatitis B patients before and after given pentoxifylline Method We conduct clinical trial on 15 chronic hepatitis 8 patients with an increased ALT (>1.3 times) and measured HA serum level before and after oral pentoxifylline 400mg tid for 4 weeks. Result After 4 weeks therapy we had result decreased of mean of ALT(79,67±19,88 vs 68,07±13,9; p=0,007'), AST(68,2±35,65 vs 51,8±16,43; p=0,001), total bilirubine (1,60±1,72 vs 1,11±0,72; p=0,005) and HA serum level (713,72±434,76 vs 554,81±330,86; p= 0,08). Conclusion Oral pentoxifylline given tor 4 weeks as antifibrotic to liver fibrosis in patients chronic hepatitis B and measured by HA serum level was not significantly enough but effective to decrease AST, ALT and bilirubine.